EUVIMEDEUVIMED entdecken
Crossref

Comparative Efficacy of Anti‐TNF Agents and Ustekinumab for Postoperative Recurrence in Crohn's Disease: 10 Years of Experience

Zihan Chen, Jianming Lin, Xiaoling Li, Jieqing Huang, Linxin Liu, Zhirong Zeng, Xiaojun Zhuang

Advanced Therapeutics · 2026-07 · 9 (7)

DOI: 10.1002/adtp.202500474 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Therapeutics, online erschienen am 12.07.2026. Verfasst von Zihan Chen und 6 weiteren Autor:innen. Die Arbeit nennt 53 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Guangdong Province.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Anti‐ tumor necrosis factor (TNF) agents are effective in preventing and treating postoperative recurrence (POR) in Crohn's disease (CD), while some patients have intolerance or fail treatment. Ustekinumab may offer an alternative, though data are limited. To compare the efficacy of anti‐TNF agents with ustekinumab for preventing and treating POR in CD. Patients who initiated anti‐TNF agents or ustekinumab within three months after surgery for POR prevention or after ileocolonoscopy with Rutgeerts score ≥ i2 for POR treatment were included. Endoscopic and clinical outcomes were evaluated. For preventing POR, 68 patients received anti‐TNF agents and 34 received ustekinumab, showing no significant differences in endoscopic POR ( p = 0.777). Ustekinumab had a lower rate of clinical POR ( p = 0.004) and biological therapy discontinuation ( p < 0.001). For treating POR, 35 received anti‐TNF agents and 27 received ustekinumab, with no significant differences in endoscopic improvement ( p = 0.632) or remission ( p = 0.285). Ustekinumab showed a higher clinical treatment success ( p = 0.004). Among 12 patients switching to ustekinumab after anti‐TNF failure, 41.7% showed endoscopic remission, and 83.3% achieved clinical treatment success. Ustekinumab has better clinical outcomes and treatment persistence than anti‐TNF agents in preventing and treating endoscopic POR in CD.

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of Guangdong Province

Zitieren

APA

Chen, Z., Lin, J., Li, X., Huang, J., Liu, L., Zeng, Z., & Zhuang, X. (2026). Comparative Efficacy of Anti‐TNF Agents and Ustekinumab for Postoperative Recurrence in Crohn's Disease: 10 Years of Experience. Advanced Therapeutics, 9(7). https://doi.org/10.1002/adtp.202500474

Vancouver

Chen Z, Lin J, Li X, Huang J, Liu L, Zeng Z, et al. Comparative Efficacy of Anti‐TNF Agents and Ustekinumab for Postoperative Recurrence in Crohn's Disease: 10 Years of Experience. Advanced Therapeutics. 2026;9(7). doi:10.1002/adtp.202500474

BibTeX
@article{Chen2026,
  author = {Chen, Zihan and Lin, Jianming and Li, Xiaoling and Huang, Jieqing and Liu, Linxin and Zeng, Zhirong and Zhuang, Xiaojun},
  title = {Comparative Efficacy of Anti‐TNF Agents and Ustekinumab for Postoperative Recurrence in Crohn's Disease: 10 Years of Experience},
  journal = {Advanced Therapeutics},
  year = {2026},
  volume = {9},
  number = {7},
  doi = {10.1002/adtp.202500474}
}
Kostenlos starten →